Pharmaceutical Compositions Comprising an Amphiphilic Starch

• US 20080171083A1
• Filed: 04/14/2005
• Published: 07/17/2008
• Est. Priority Date: 04/14/2004
• Status: Abandoned Application

• Current Assignee: PharmaKodex Ltd. (Orexo AB)
• Original Assignee: Vecture Limited
• Inventors: Staniforth, John, Talwar, Naresh
• Application Number:
  US11/578,271
• Publication Number:
  US 20080171083A1
• Time in Patent Office: Days
• US Class Current: 424/456
• CPC Class Codes: A61K 9/2013 Organic compounds, e.g. phospholipids, fats
• CPC Class Codes: A61K 9/2059 Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Abstract

The present invention relates to controlled or sustained release solid pharmaceutical compositions, to pharmaceutical excipients for use in the manufacture of such compositions and to methods of producing such compositions and excipients. The controlled or sustained release excipients include a release controlling excipient comprising an amphiphilic starch.

Claims

1. :

A controlled or sustained release solid pharmaceutical excipient, comprising a release controlling excipient comprising an amphiphilic starch.

2. :

An excipient as claimed in claim 1, wherein the amphiphilic starch is an alkyl, alkenyl, aralkyl or aralkenyl succinate or glutarate starch.

3. :

An excipient as claimed in claim 1, wherein the amphiphilic starch is or includes a C₆ to C₁₆ alkenyl succinate starch.

4. :

An excipient as claimed in claim 3, wherein the C₆ to C₁₆ alkenyl succinate starch is n-octenyl succinate starch or sodium octenyl succinate starch.

5. :

An excipient as claimed in claim 1, further comprising at least one oily or fatty component.

6. :

An excipient as claimed in claim 5, wherein the oily or fatty component is or includes a fatty acid, derivative or salt, a mineral oil, a vegetable oil or a wax.

7. :

An excipient as claimed in claim 6, wherein the vegetable oil is a hydrogenated vegetable oil.

8. :

An excipient as claimed in claim 7, wherein the hydrogenated vegetable oil is or includes hydrogenated cottonseed oil, hydrogenated castor oil, hydrogenated palm oil or hydrogenated soybean oil.

9. :

An excipient as claimed in claim 5, wherein the fatty or oily component is or includes sodium stearyl fumarate, calcium stearate, magnesium stearate, glyceryl monooleate, glyceryl monostearate, glyceryl palmitostearate, medium chain glycerides, mineral oil or stearyl alcohol.

10. :

An excipient as claimed in claim 5, wherein the at least one oily or fatty component is present in an amount equivalent to up to 40% of the amount of amphiphilic starch in the excipient.

11. :

An excipient as claimed in claim 1, in a free-flowing powdered or granular form.

12. :

An excipient as claimed in claim 1, for use in the preparation of a controlled or sustained release solid pharmaceutical composition.

13. :

An excipient as claimed in claim 12, being sufficiently compressible for use in the formation of tablets by direct compression or by compression of a granulate formed from the excipient.

14. :

A controlled or sustained release solid pharmaceutical composition, comprising a pharmaceutically active agent and an excipient as claimed in claim 1.

15. :

A composition as claimed in claim 14, wherein the composition comprises at least 50% active agent by weight.

16. :

A composition as claimed in claim 15, wherein the composition comprises at least 60, 70 or 80% active agent by weight.

17. :

A composition as claimed in claim 14, wherein the composition comprises an enzyme activity reducing agent or an enzyme inhibitor.

18. :

A composition as claimed in claim 17, wherein the enzyme inhibitor is an amylase inhibitor.

19. :

A composition as claimed in claim 17, wherein the composition includes an acid.

20. :

A composition as claimed in claim 19, wherein the acid is citric acid, succinic acid, tartaric acid, fumaric acid, maleic acid, lactic acid or ascorbic acid.

21. :

A composition as claimed in claim 17, wherein the composition includes ascorbic acid, acarbose, phaseolamine, tendaminstat, maltose, maltotriose or nojirimycin.

22. :

A composition as claimed in claim 14, further comprising a gas-generating agent which reacts with an acid to generate a gas.

23. :

A composition as claimed in claim 22, wherein the gas-generating agent is sodium bicarbonate or calcium carbonate.

24. :

A composition as claimed in claim 14, wherein the pharmaceutically active agent is an antiepileptic, antiasthmatic, antiulcer, analgesic, antihypertensive, antibiotic, antipsychotic, anticancer, antimuscarinic, diuretic, antimigraine, antiviral, anti-inflammatory, sedative, antidiabetic, antidepressant, antihistaminic, an antialzheimers drug or a lipid lowering drug.

25. :

A composition as claimed in claim 24, wherein the active agent is gabapentin, galantamine, topiramate, oxycodone, oxymorphone, hydromorphone or methylphenidate.

26. :

A composition as claimed in claim 14, wherein the pharmaceutically active agent is present in an amount ranging from 5 to 1200 mg.

27. :

A composition as claimed in claim 14, wherein the amphiphilic starch comprises from about 2, 5, 7 or 10% to about 80, 85, 90, 95 or 99% by weight of the composition.

28. :

A composition as claimed in claim 14, comprising an oily or fatty component in an amount from about 2, 5, 7 or 10% to 40, 45, 50, 55 or 60% by weight of the composition, preferably from about 5-20% by weight of the composition.

29. :

A composition as claimed in claim 14, wherein the composition is in the form of a tablet, a hard gelatin capsule, an extrudate, pellets, a powder, granules, or a suppository.

30. :

A composition as claimed in claim 29, wherein the composition is in the form of a tablet for ingestion into the gastrointestinal tract.

31. :

A composition as claimed in claim 14, further comprising a lubricant, a binder, a disintegrating agent, a colouring agent, a flavouring agent, a preservative, a stabiliser, a glidant, a filler, or a bulking agent.

32. :

A composition as claimed in claim 14, coated with a film of a coating agent.

33. :

A composition as claimed in claim 32, wherein the coating is substantially unbroken.

34. :

A composition as claimed in claim 32, wherein the coating comprises a polyvinyl alcohol, a polyacrylate, a polymethacrylate, a cellulose or a cellulose derivative.

35. :

A method of preparing a controlled or sustained release solid pharmaceutical composition comprising the use of an excipient as claimed in claim 1.

36. :

A method as claimed in claim 35, wherein the controlled or sustained release solid pharmaceutical composition is a controlled or sustained release solid pharmaceutical composition as claimed in claim 14.

37. :

A method as claimed in claim 35, comprising directly compressing a mixture comprising the excipient into a controlled or sustained release solid pharmaceutical tablet.

38. :

A method as claimed in claim 35, comprising forming a granulate comprising the excipient and compressing said granulate into a controlled or sustained release solid pharmaceutical tablet.

39. :

A method as claimed in claim 35, further comprising the step of coating the tablet.

40. :

A pharmaceutical composition whenever prepared by a method as claimed in claim 35.

41. :

A controlled or sustained release gabapentin formulation, comprising from 2, 5, 7 or 10% to 75, 80, 85, 90 or 95% of sodium octenyl succinate starch.

42. :

A formulation as claimed in claim 41, comprising a pharmaceutically effective amount of gabapentin, about 5, 7, 10 or 15% to 70, 75, 80 or 85% of sodium octenyl succinate starch and about 5, 7, 10 or 15% to 30, 35, 40, 45 or 50% of oily or fatty component by weight of the composition.

43. :

A controlled or sustained release galantamine formulation, comprising from 2, 5, 7 or 10% to 75, 80, 85, 90 or 95% of sodium octenyl succinate starch.

44. :

A formulation as claimed in claim 43, comprising a pharmaceutically effective amount of galantamine, and about 65, 70, 75, 80 or 85% of sodium octenyl succinate starch.